Document is current
Any future updates will be listed below
-
Authors
Boyer, Olivier
Bensoussan, Daniele
Bönig, Halvard
Chabannon, Christian https://orcid.org/0000-0002-3755-4889
Clémenceau, Béatrice
Cuffel, Alexis
Dachy, Guillaume https://orcid.org/0000-0002-1668-975X
de Vos, John https://orcid.org/0000-0003-1880-4130
Derenne, Sophie
Diana, Jean-Sébastien
Dougé, Aurore
Deramoudt, Laure
Ferrand, Christophe https://orcid.org/0000-0003-0119-3919
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Galaine, Jeanne
Galy, Anne
Giverne, Camille
Martinet, Jérémie
Marton, Chrystel
Larghero, Jérôme
Reppel, Loïc
Viel, Sébastien https://orcid.org/0000-0002-5085-443X
Yakoub-Agha, Ibrahim
Deschamps, Marina https://orcid.org/0000-0002-0564-0926
- License Information
-
More Information
Article History
Received: 9 August 2024
Revised: 20 November 2024
Accepted: 16 December 2024
First Online: 25 January 2025
Competing interests
: OB received research funding and/or honoraria from Argenx, BMS, CSL Behring, Egle Tx, OGD2 and UCB. DB: Declares no conflict of interest in the field of CAR T cells. HB: Licensing fees and royalties from Medac; research support from Erydel, Miltenyi, Sandoz-Hexal (a Novartis company); honoraria and speaker fees from Medac, Miltenyi, Novartis and Terumo BCT; consultancy and membership of advisory boards for Boehringer-Ingelheim, Celgene (a BMS company), Medac, Novartis and Sandoz-Hexal; stock ownership in Healthineers CC: received research funding and honoraria (institutional or personal) for participation in advisory boards and speakers bureau from BMS, Janssen Pharmaceuticals, Kite/Gilead, Miltenyi Biotec, Novartis. BC: Declares no conflict of interest in the field of CAR T cells. AC: Declares no conflict of interest. GD: Declares no conflict of interest in the field of CAR T cells. JSD: Declares no conflict of interest in the field of CAR T cells. SD: Declares no conflict of interest in the field of CAR T cells. JDV: Declares no conflict of interest in the field of CAR T cells. AD: Declares no conflict of interest in the field of CAR T cells. LD: Declares no conflict of interest in the field of CAR T cells. CF: shareholder and employee Advesya. EF: received honoraria for participation in advisory boards and speaker’s bureau from Kite/Gilead, Novartis, Alexion, Astellas, GSK. JG: Declares no conflict of interest in the field of CAR T cells. AG: Declares no conflict of interest in the field of CAR T cells. CG: Declares no conflict of interest in the field of CAR T cells. JM: Declares no conflict of interest in the field of CAR T cells. CM: Declares no conflict of interest. JL: received honoraria from Novartis, Kite/Gilead, BMS, Janssen, Miltenyi Biotec. LR: Declares no conflict of interest in the field of CAR T cells. SV: Declares no conflict of interest. IYA: received honorarium from Novartis, BMS, KITE and Milteny Biomedecine. MD: shareholder and employee Advesya.
